Pure red cell aplasia (PRCA) is a well-known although infrequent hematologic complication after allogeneic bone marrow transplantation. PRCA occurs in cases of major ABO-mismatch between donor and recipient and is believed to be due to inhibition of donor erythroid progenitors by residual host isohemagglutinins. We report a 10-year-old boy with post-hepatitis aplastic anemia (AA) who developed PRCA after HLA-matched familial peripheral blood stem cell transplantation (SCT) following conditioning with Cph 200 mg/kg + ATG 90 mg/kg. Granulocyte engraftment occurred on day +18, platelet engrafted on day +40, while reticulocytopenia at 0% persisted until day +118, and erythroid precursors were totally absent from bone marrow. After a single dose of rituximab 200 mg/m 2 administered on day +118 PRCA resolved and on day +132 the reticulocytes rose to 5.7%. On day +139 the Hb reached 137 g/l and the erythroid lineage in BM increased to 21%. We conclude that due to the rapid recovery from PRCA and lack of side effects, rituximab should be tried as firstline treatment of PRCA after allo-SCT. Bone Marrow Transplantation (2002) 30, 405-407. doi:10.1038/sj.bmt.1703668 Keywords: pure red cell aplasia; allogeneic stem cell transplantation; rituximab Pure red cell aplasia (PRCA) is an infrequent but wellrecognized complication of allogeneic bone marrow transplantation. Most cases of PRCA occur after transplantations with major donor-recipient ABO mismatch and are due to the long persistence of residual titers of natural recipient anti-A, 1 or very rarely, anti-B antibodies, 2 causing inhibition of donor erythroid progenitors. Additional risk factors include use of reduced intensity conditioning and immunosuppression with CsA in the post-transplant
period. 3, 4 Reported therapeutic options for post-transplant PRCA are plasmapheresis, 5, 6 high doses of erythropoietin, 7, 8 donor lymphocyte infusions, 9,10 ATG, 11, 12 CsA withdrawal, 4 and glucocorticoids. 2 As a general rule, recovery from PRCA coincides with disappearance of anti-A or anti-B isohemagglutin. We report a case of successful treatment of PRCA after BMT with humanized anti-CD20 antibody rituximab.
Case report
A 10-year-old boy was diagnosed with pancytopenia (Hb 19 g/l, platelets 3000/mm 3 , granulocytes 486/mm 3 in January 2001), 3 months after moderately severe icteric seronegative hepatitis. In April 2001 he was referred in our hospital. His CBC showed Hb 84 g/l (after transfusion), reticulocytes 0.2%, WBC 1600/mm 3 , granulocytes 256/mm 3 , platelets 5000/mm 3 . Bone marrow aspiration and biopsy showed empty bone marrow with no leukemic cells. The ALT and AST were elevated to 55 and 84 UI/l, respectively (N <35 U/l), bilirubin was normal, and LDH was elevated to 2 N. Serologic markers of HBV, HCV and HGV were negative while anti-HAV IgG was positive. Serum anti-CMV antibodies were not detected. Ham's test was negative. There were no exposures to elicit drugs. Test for chromosome fragility with diepoxybutane was negative. Thus, a diagnosis of severe hepatitis-associated aplastic anemia was made. HLA typing revealed a serologically and molecularly matched 12-year-old sister. The blood group of patient was O+, whereas the donor was A+. Pretransplant anti-A titers were not studied. The total number of transfusions before transplantation was 7 and only O group products were utilized.
The child was nursed in a laminar air flow room. Oral fluconazole, amoxicillin and ciprofloxacin were used for antimicrobial prophylaxis starting on day −7. Acyclovir 250 mg/m 2 i.v. three times a day was given from day +1 until day +21, and orally thereafter. The conditioning regimen consisted of cyclophosphamide 50 mg/kg on days −5 to −2 (total dose 200 mg/kg b.w.) and antithymocyte globulin (ATGAM, Pharmacia-Upjohn, Kalamazoo, USA) 30 mg/kg on days −3 to −1 (total dose 90 mg/kg bw). To prevent GVHD cyclosporin A (Sandimmune; Novartis Pharma, Basle, Switzerland) 3 mg/kg by continuous i.v. infusion was started on day −1 and methotrexate 10 mg/m 2 i.v. was given on days +1, +4 and +7. In order to avoid any cell loss due to the procedure of red cell depletion we opted to use G-CSF-mobilized peripheral blood progenitor cells rather than bone marrow. The donor was stimulated with G-CSF (Granocyte; Rhone-Poulenc-Rorer, France) 10 g/kg bw day for 5 days and stem cell collection was performed on day 5 on a Fenwal 3000+ cell separator. The total number of mononuclear cells infused was 4.2 ϫ 10 8 /kg and the CD34 + cell count was 5.9 ϫ 10 6 /kg. The post-transplant course was uneventful, except for neutropenic fever treated with cefepime. G-CSF 5 g/kg bw day s.c. was started on day +14 and continued until day +22, when granulocytes reached >5000/l. Granulocyte engraftment (ANC >500/l) was achieved on day +18 and platelet engraftment (platelets >20 000/l) was delayed until day +40. Mild cutaneous rash and diarrhea appeared on day +16 and were treated with methylprednisolone 1 mg/kg day i.v. for 14 days. After cessation of steroids, a rise in ALAT and ASAT was noted which peaked to 20 N on day +39, with no changes in bilirubin levels. Methylprednisolone 1 mg/kg day i.v. was resumed for 21 days leading to rapid normalization of liver enzymes. Due to a low trough level of CsA (27 ng/ml) and slight rise of creatinine and urea above the upper normal values for age precluding dose adjustment, we added MMF (CellCept; F Hoffmann-La Roche, Basle, Switzerland) 30 mg/kg bw day orally on day +70 in order to prevent rejection and ensure better prophylaxis of cGVHD.
On day +105 the patient was still dependent on RBC transfusions and the reticulocyte count was 0%. Bone marrow aspiration showed normal myeloid and megakaryocytic lineage with absent erythroid cells. The blood group remained O and the anti-A isohemagglutinin titer was 1:4. A diagnosis of PRCA was made. Cytogenetics of the bone marrow showed a normal female karyotype in all 16 metaphases analyzed. CMV-viremia assessed by PCR was nega- tive. Serologic or virologic searches for parvovirus B19 were not performed. On day +118 the Hb level was still 70 g/l, reticulocytes 0% and rituximab (Mabtera; F Hoffman-La Roche, Switzerland) 200 mg/m 2 was infused over 1 h with no side-effects. On day +128, the Hb began to rise and the reticulocyte count rose to 2% and peaked at 5.7% 4 days later. At this point, the blood group switched to A+ and anti-A titers dropped to undetectable levels. Twentyone days after the rituximab infusion, the Hb rose to 137 g/l and a control bone marrow aspiration showed 21% erythroid cells, 54% myeloid lineage and a normal number of megakaryocytes. At the time of writing, 210 days after BMT, the patient is doing well with no cGVHD and his blood counts are essentially normal.
Discussion
Development of PRCA aplasia after ABO-mismatched BMT poses difficult therapeutic problems. Most approaches reported to be effective are costly, time-and resources-consuming and many of them are hazardous with respect to development of severe immunosuppression (ATG, steroids), GVHD (DLI, CsA withdrawal) or viral infections (plasma exchange). In addition, not all of these approaches have reproducible effectiveness. For example, erythropoietin was reported to be effective by some authors, 7, 8 while others 4 have demonstrated the opposite. The most plausible explanation of PRCA after BMT is persistence of isohemagglutinins produced by residual memory B cells and plasma cells not destroyed by the conditioning regimen. Interestingly, few cases of PRCA have been reported in recipients transplanted for AA, 2,3 although AA patients very rarely receive myeloablative conditioning. Probably cyclophosphamide, at a dose 200 mg/kg that is the almost universal component of conditioning for AA sufficiently suppresses plasma and memory B cells. In the event of development of isohemagglutinin-mediated PRCA, the goal of therapy is to exhaust the residual pool of cells producing isohemagglutinins. Recently, rituximab has been shown to be effective in a number of patients with autoimmune antibody-mediated syndromes, such as ITP, 13 and hemolytic anemia with PRCA.
14 Hence, we hypothesized that it could be a good candidate in isohemagglutinin-mediated PRCA after BMT. Our case demonstrates that this approach can indeed be viable as impressively fast recovery of erythropoiesis was achieved in our patient, paralleled with the disappearance of anti-A antibodies. This fast recovery contrasts sharply with the slow responses achieved with erythropoietin or plasma exchanges. It could of course be no more than coincidence, but the fact that a spontaneous drop in anti-A titers occurs much later, usually between days 160 and 220 4 after BMT or even later 8 argues against this. Recently Bolan et al 3 hypothesized that CsA withdrawal and adding mycofenolate mofetil (MMF) might be useful in promoting suppression of production of isohemagglutinins. Interestingly, in our patient, MMF was added to CsA 48 days before the anti-CD20 infusion, without any effect on PRCA.
In conclusion, we report the case of spectacularly rapid recovery from PRCA after a single dose of rituximab. We consider that due to the apparent lack of any hazardous effects as previously reported with other effective therapeutic approaches, rituximab deserves to be tested as a firstline treatment for PRCA mediated by residual host isohemagglutinins.
